جست‌وجوی استاد و پژوهشگر

• Pharmacogenomics
• Cancer Research
• Molecular Biology
• +۳ مورد دیگر

Cristian Andrés Acevedo Castillo is an Assistant Professor at the Faculty of Medicine, University of Chile , affiliated with the Molecular and Clinical Pharmacology Program and Maternal-Child Research Institute. His academic career spans teaching and research in pharmacogenomics, cancer genetics, and urology. Physician-Surgeon , University of Chile (1998) Medical Specialty , University of Chile (2004) His research interests focus on Pharmacogenomics , exploring genetic polymorphisms and environmental factors in cancer susceptibility and chemotherapy toxicity. He investigates Cancer Genomics (prostate/testicular tumors), Molecular Biomarkers , and Urological Interventions (e.g., lithotripsy, BPH treatments). His work also addresses Genotype-Environment Interactions in disease risk and Biomedical Imaging for clinical prostate assessment. The 15 most recent publications (as of 2006–2021) highlight his expertise in pharmacogenetics, cancer risk factors, and urological treatments. Keywords span Cancer Research , Pharmacogenomics , and Urology , with subfields like Genetic Polymorphisms , Chemotherapy Toxicity , and Prostate Imaging . His studies often analyze gene-gene/environment interactions in Chilean populations. He has secured grants (FONDECYT Regular 1140434, 1070756) and contributed to postgraduate teaching courses on cancer biology and pharmacogenomics. His lab affiliations include the Molecular and Clinical Pharmacology Program, emphasizing translational research between basic science and clinical applications.

• Infectious Diseases
• HIV
• Epidemiology
• +۳ مورد دیگر

Mette Vang Larsen serves as a Clinical Associate Professor in the Department of Clinical Medicine at the University of Copenhagen's Faculty of Health and Medical Sciences. Based at Blegdamsvej 3 in Copenhagen, she specializes in internal medicine with a focus on infection medicine, particularly HIV, hepatitis, and tuberculosis research within the Capital Region of Denmark (Region H). Her research centers on infectious disease epidemiology, including HIV and hepatitis co-infections, molecular characterization of bacterial pathogens, and the impact of injecting drug use on disease progression. She has made significant contributions to the Danish HIV cohort study, enabling large-scale population-based research on immunocompromised patients and pathogen genomics. Her publication record (2008-2012) reveals a consistent focus on HIV-related infectious complications, with high-impact work on viral genotypes, mortality predictors, and bacterial infections. The 2012 multilocus sequence typing paper has garnered over 1,800 Scopus citations, establishing it as a cornerstone in genomic epidemiology methodology. While no specific scientific awards are documented in available sources, her research has been widely disseminated across academic platforms including Mendeley (1,518+ readers), Scopus, policy documents, and Wikipedia. She maintains extensive collaborations within Denmark's healthcare research ecosystem through Region H and the university. Information regarding graduate student advising and grant funding is absent from current records, though her leadership in nationwide cohort studies indicates active participation in multidisciplinary research teams and projects involving epidemiological surveillance and treatment outcome analysis.

• HIV/AIDS
• Cancer
• Implementation Science
• +۵ مورد دیگر

Raul U. Hernandez-Ramirez is a Research Scientist in Biostatistics at Yale University's Center for Methods in Implementation and Prevention Science (CMIPS) and Director of the Dissemination and Implementation Science Methods (DISM) Core at the Center for Interdisciplinary Research on AIDS (CIRA). He is affiliated with the Yale Cancer Center and the Yale Institute for Global Health, where he contributes to research at the intersection of HIV/AIDS, cancer, and implementation science. Dr. Hernandez-Ramirez completed his PhD in Public Health (Chronic Disease Epidemiology) at Yale, following specialized training at the National Cancer Institute and in implementation science methodologies. His educational background includes an MSc in Epidemiology and a BSc in Nutrition, with prior research experience at Mexico's National Institute of Public Health. His research focuses on developing and applying causal inference methods for HIV prevention interventions, examining dietary factors related to gastric cancer risk through the international Stomach cancer Pooling (StoP) Project, and implementing evidence-based practices in low-resource settings. Much of his work involves international collaboration, particularly with Mexican institutions. Dr. Hernandez-Ramirez's publication record shows consistent output in high-impact journals, with recent work spanning gastric cancer epidemiology, HIV implementation science, environmental health methods, and global health applications. His research demonstrates strong methodological rigor and cross-disciplinary collaboration, particularly with biostatisticians and epidemiologists at Yale. As Director of the DISM Core, he provides critical methodological support for implementation science projects, particularly those focused on Ending the HIV Epidemic (EHE) priority areas. His expertise bridges statistical methodology with practical implementation challenges in real-world settings. His research team involves collaborations across multiple Yale departments and international institutions, with a particular emphasis on capacity building in low- and middle-income countries. The DISM Core under his leadership serves as a hub for implementation science methodology at Yale.

Sam Hoganمشاهده پروفایل

مدرس

• Epidemiology
• Infectious Diseases
• Public Health
• +۴ مورد دیگر

Sam Hogan is a Lecturer in Epidemiology at Western Sydney University and a PhD candidate at the university's Translational Health Research Institute (THRI). His academic journey includes roles as a research assistant investigating healthcare access among CALD communities and breast cancer screening behaviors, along with extensive teaching experience in epidemiology and public health programs. Previously, he served as the Population Health tutor for WSU Medical School (2019-2023). Educational background: PhD Candidate, Western Sydney University (current) Master of Epidemiology, Western Sydney University Bachelor of Liberal Arts and Science (Immunobiology major), University of Sydney His research focuses on infectious disease epidemiology and public health strategies, employing both quantitative and qualitative methodologies. Primary interests include: Hepatitis B/HIV dynamics - Prevalence studies, risk factor analysis, and public health interventions in Nepal Health equity - Healthcare access for marginalized populations and screening behavior analysis Preventive health - Mammographic screening optimization for women with obesity/disabilities Publication trends show concentrated work in viral epidemiology (2019-2021), evolving toward public health interventions (2023-2024). His recent articles demonstrate methodological diversity, including systematic reviews, meta-analyses, and co-design frameworks for health programs. Affiliated roles: Current Lecturer position with teaching responsibilities Active PhD researcher at THRI Former research assistant and casual academic roles

Scott D. Olsonمشاهده پروفایل

دانشیار

• Mesenchymal stem cell therapies
• Immunomodulation
• Traumatic Brain Injury treatment
• +۵ مورد دیگر

Dr. Scott D. Olson is an Associate Professor at the University of Texas Health Science Center in the Department of Pediatric Surgery, where he has been conducting research since September 2011. His academic journey includes a BS in Biochemistry from Texas Christian University, a PhD in Molecular and Cellular Biology from Tulane University, and postdoctoral training in the Stem Cell Program at University of California at Davis Health System. Dr. Olson's research centers on mesenchymal stem cells (MSCs) and their therapeutic applications, particularly for Traumatic Brain Injury (TBI). His work explores how MSCs can immunomodulate and restore homeostasis, with a focus on their impressive ability to control immune system activation in inflammatory conditions. His laboratory conducts comparative studies of different MSC preparations to identify optimal therapeutic candidates and investigates MSC interactions with immune cells, particularly monocytes and macrophages. Dr. Olson's research program has evolved from studying MSC applications for Huntington's Disease at UC Davis to focusing on TBI treatment at UTHealth. His work demonstrates a consistent theme of leveraging MSCs' innate therapeutic abilities to develop improved cellular therapies. The research shows particular promise in conditions involving prolonged or exaggerated inflammation, where MSCs have demonstrated significant efficacy in clinical trials. His scientific contributions span multiple disciplines including regenerative medicine, neurology, immunology, and trauma surgery. Dr. Olson has published extensively on MSC therapies, with recent work expanding into synthetic biology approaches and novel drug delivery systems. His collaborative research extends across multiple institutions and specialties, reflecting the interdisciplinary nature of modern regenerative medicine research. Dr. Olson's laboratory focuses on three primary research directions: Comparing different MSC and MSC-like cell preparations to identify optimal therapeutic candidates Studying MSC interactions with specific immune cell populations, particularly their influence on monocyte and macrophage phenotype Developing mixed cell preparations using selectively permeable scaffolds for implantable therapeutic constructs His work aims to translate basic MSC research into clinical applications, with a particular emphasis on improving treatments for Traumatic Brain Injury through better understanding of MSC mechanisms and therapeutic potential.

Asher Schranzمشاهده پروفایل

استادیار

• Infectious Diseases
• Substance Use Disorders
• Infective Endocarditis
• +۷ مورد دیگر

Asher Schranz, MD, MPH is an Assistant Professor of Medicine in the Division of Infectious Diseases at the University of North Carolina at Chapel Hill School of Medicine. His clinical practice focuses on infectious diseases with particular expertise in endovascular infections, viral hepatitis, and HIV, with a special interest in caring for patients with substance use disorders. Dr. Schranz's research centers on the intersection of infectious diseases and substance use disorders, specifically examining outcomes following severe injection drug-related infections such as infective endocarditis and bone, joint, and spine infections. His work utilizes large datasets and qualitative methods to develop patient-centered approaches to disease prevention, inpatient addiction care, harm reduction, and long-term antibiotic delivery. He also investigates Hepatitis C epidemiology, HIV health services research, and clinical practice issues related to outpatient parenteral antimicrobial therapy (OPAT). His research portfolio demonstrates significant focus on drug use-associated infective endocarditis, viral hepatitis treatment in people who inject drugs, and the complex interactions between substance use disorders and infectious disease outcomes. Recent publications highlight his work on long-term infection risks, mortality patterns, surgical decision-making, and innovative treatment coordination approaches for this vulnerable patient population. Dr. Schranz has received recognition for his contributions to understanding the connections between prescription opioids and infectious diseases, as well as his work addressing the rural opioid epidemic's impact on HIV and Hepatitis C transmission. He collaborates extensively with public health professionals, cardiac surgeons, addiction medicine specialists, epidemiologists, and health behavior researchers to advance care for patients with substance use disorders and infectious complications. His educational background includes an MD from the University of Pennsylvania, residency at New York University/Bellevue Hospital, fellowship at UNC Chapel Hill, and an MPH from UNC's Gillings School of Global Public Health.

Keith Johnstonمشاهده پروفایل

استاد

• Materials Chemistry
• Nanoparticle Synthesis
• Colloid and Interface Science
• +۳ مورد دیگر

Keith Johnston is Professor and Cockrell Family Dean's Chair in Engineering Excellence in the Department of Chemical Engineering at the University of Texas at Austin's Cockrell School of Engineering. His research integrates materials chemistry, colloid science, and engineering to develop advanced nanoparticle systems for energy and biomedical applications. His educational background includes: B.S. from the University of Michigan (1977) Ph.D. from the University of Illinois (1981) Professor Johnston's research focuses on controlling nucleation, growth, and passivation of metal/metal oxide nanoparticles using ligands and polymeric stabilizers. Key areas include nanocluster assembly for novel materials, nanoparticle behavior at liquid/solid interfaces, subsurface nanotechnology for CO 2 sequestration and oil recovery, electrocatalysts for energy storage, and reversible protein nanoclusters for drug delivery. His biomedical work targets biodegradable plasmonic nanoclusters for cancer imaging/therapy that clear through kidneys. Analysis of his 2014-2017 publications reveals strong emphasis on CO 2 -in-water foams for subsurface applications (50% of recent work), protein stabilization for biologics delivery (30%), and electrocatalyst design (20%). These studies bridge fundamental colloid science with practical engineering challenges in energy and healthcare. His major recognitions include: National Academy of Engineering election (2011) AIChE's 100 Chemical Engineers of the Modern Era (2008) Fellow of American Institute of Medical and Biological Engineers (2013) Multiple AIChE awards including Industrial Gases Technology Institute Award (2004) University of Texas Faculty Excellence Awards (1990, 1995) Professor Johnston leads an active research group with significant interdisciplinary collaborations, particularly with petroleum engineers on subsurface applications. His work attracts substantial funding for developing earth-abundant catalysts and low-water-usage technologies. The lab maintains strong industry partnerships focused on translating nanoparticle research into energy and medical solutions. The research group operates specialized facilities for nanoparticle synthesis, colloid characterization, and subsurface simulation. Current projects emphasize greener oil recovery with minimal water usage, kidney-clearable imaging agents, and scalable electrocatalyst production. Future directions target commercialization of nanoparticle-stabilized CO 2 foams and self-administered biologic delivery systems.